drugset
drugset / Trial / NCT02135588

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

NCT02135588 ↗

Phase 1 Unknown 10 enrolled Eastern Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of intrapleural dornase alfa and tPA administered to patients with clinical failure of small-bore chest tube with persistent pleural effusions or malignancy-related loculated effusion to improve pleural drainage.

Timeline

Start
2013-10
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 10 mg Other
Subject dornase alfa Protein / enzyme biologic 5 mg Other

Indications

cancer